ABOUT US
ABOUT US
Our Mission
To improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform.
Transforming the Future for Patients
Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins.
For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
We Are Undeterred by “Undruggable”
We’ve developed a broad technology platform focused on high-value targets to deliver more potent therapies and address the majority of proteins that evade inhibition—including those that have been deemed “undruggable” by traditional approaches.
Our lead programs are currently focused on the receptors associated with prostate and breast cancers.
At Arvinas, we work every day to unlock the full potential of PROTAC® protein degraders, developing a robust pipeline and partnering with the world’s leading drug development companies to bring new possibilities where they are needed most.
1O Years of Scientific Discovery
Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degraders
Two Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies
Arvinas initiates first registrational study with vepdegestrant
Bavdegalutamide and vepdegestrant are currently under investigation. Their safety and effectiveness have not yet been established.
